Immunovant (IMVT) Earnings Date & Reports

A.I. Advisor

published Earnings

IMVT is expected to report earnings to rise 11.31% to -58 cents per share on November 07

Q3'24

Est.

$-0.59

Q2'24

Est.

$-0.52

Q1'24

Missed

by $0.09

Q4'23

Beat

by $0.07

Q3'23

Est.

$-0.45

The last earnings report on August 06 showed earnings per share of -52 cents, missing the estimate of -52 cents. With 746.77K shares outstanding, the current market capitalization sits at 4.10B.

View a ticker or compare two or three

Compare

IMVT

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if shorted

View Trends For IMVT
(Try 14 days for $1 only)

Ad is loading...

A.I.Advisor

published price charts

View to see Real Time Patterns for IMVT (Try 14 days for $1 only)

A.I. Advisor

published General Information

General Information

a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases.

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

320 West 37th Street

Phone

+1 917 580-3099

Employees

164

Web

https://www.immunovant.com